CO2017004516A2 - Anticuerpos anti-ox40 humanizados - Google Patents
Anticuerpos anti-ox40 humanizadosInfo
- Publication number
- CO2017004516A2 CO2017004516A2 CONC2017/0004516A CO2017004516A CO2017004516A2 CO 2017004516 A2 CO2017004516 A2 CO 2017004516A2 CO 2017004516 A CO2017004516 A CO 2017004516A CO 2017004516 A2 CO2017004516 A2 CO 2017004516A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- humanized anti
- methods
- producing
- cancer treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062431P | 2014-10-10 | 2014-10-10 | |
| PCT/US2015/054490 WO2016057667A1 (en) | 2014-10-10 | 2015-10-07 | Humanized anti-ox40 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017004516A2 true CO2017004516A2 (es) | 2017-09-29 |
Family
ID=55130798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0004516A CO2017004516A2 (es) | 2014-10-10 | 2017-05-04 | Anticuerpos anti-ox40 humanizados |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9738723B2 (OSRAM) |
| EP (1) | EP3204422B1 (OSRAM) |
| JP (2) | JP6794348B2 (OSRAM) |
| KR (1) | KR20170064550A (OSRAM) |
| CN (1) | CN107074953A (OSRAM) |
| AR (1) | AR102239A1 (OSRAM) |
| AU (1) | AU2015328090A1 (OSRAM) |
| BR (1) | BR112017007170A2 (OSRAM) |
| CA (1) | CA2963798A1 (OSRAM) |
| CL (1) | CL2017000885A1 (OSRAM) |
| CO (1) | CO2017004516A2 (OSRAM) |
| ES (1) | ES2914177T3 (OSRAM) |
| GB (1) | GB2536324A (OSRAM) |
| IL (1) | IL251537A0 (OSRAM) |
| MX (1) | MX2017004715A (OSRAM) |
| RU (1) | RU2709742C2 (OSRAM) |
| SG (1) | SG11201702826XA (OSRAM) |
| TW (1) | TW201619200A (OSRAM) |
| WO (1) | WO2016057667A1 (OSRAM) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD20180107A2 (ro) | 2013-03-18 | 2019-06-30 | Biocerox Products B.V. | Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora |
| AU2014364606A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| MX2016012779A (es) | 2014-03-31 | 2017-04-27 | Genentech Inc | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. |
| BR112017013189B1 (pt) * | 2015-01-08 | 2024-03-05 | Genmab A/S | Agentes agonísticos de ligação ao receptor de tnf |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| TWI716405B (zh) | 2015-05-07 | 2021-01-21 | 美商艾吉納斯公司 | 抗ox40抗體及其使用方法 |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| MX2017015041A (es) | 2015-05-29 | 2018-02-26 | Squibb Bristol Myers Co | Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos. |
| MA43017A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf |
| CN108137684B (zh) | 2015-10-15 | 2022-03-08 | 苏州丁孚靶点生物技术有限公司 | 抗ox40抗体及其应用 |
| EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| IL321475A (en) | 2016-05-06 | 2025-08-01 | Medimmune Llc | Bispecific binding proteins and their uses |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| AU2017298483A1 (en) * | 2016-07-20 | 2019-02-07 | Igm Biosciences, Inc. | Multimeric OX40 binding molecules and uses thereof |
| EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| CR20190330A (es) | 2016-12-15 | 2019-12-19 | Abbvie Biotherapeutics Inc | Anticuerpos anti-ox40 y sus usos |
| EA201991207A1 (ru) | 2016-12-19 | 2019-12-30 | Гленмарк Фармасьютикалс С.А. | Новые агонисты tnfr и их применение |
| WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| JP7402691B2 (ja) | 2017-04-20 | 2023-12-21 | アーデーセー セラピューティクス ソシエテ アノニム | 抗ｃｄ２５抗体薬物複合体による併用療法 |
| KR20200074214A (ko) * | 2017-11-01 | 2020-06-24 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체 |
| CA3084394A1 (en) * | 2017-11-24 | 2019-05-31 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ox40 antibodies and uses thereof |
| JP7362614B2 (ja) | 2017-12-29 | 2023-10-17 | エーピー バイオサイエンスィズ インコーポレイテッド | 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質 |
| CN108218990B (zh) * | 2017-12-29 | 2021-03-02 | 南京优迈生物科技有限公司 | 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用 |
| CN110092832B (zh) * | 2018-01-29 | 2020-03-31 | 康源博创生物科技(北京)有限公司 | 抗ox40抗体及其用途 |
| CN111936507B (zh) * | 2018-03-23 | 2022-11-01 | 苏州丁孚靶点生物技术有限公司 | Ox40抗原多肽及其用途 |
| PE20210665A1 (es) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | Anticuerpos contra mica y/o micb y sus usos |
| JP7611700B2 (ja) | 2018-03-27 | 2025-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | 紫外線シグナルを使用した力価のリアルタイムモニタリング |
| CA3103040A1 (en) | 2018-05-11 | 2019-11-14 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing same, and use thereof |
| CN112566935B (zh) * | 2018-05-23 | 2024-12-13 | 百济神州有限公司 | 抗ox40抗体和使用方法 |
| BR112020023846A2 (pt) | 2018-05-23 | 2021-04-13 | Adc Therapeutics Sa | Adjuvante molecular |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| MX2021000399A (es) | 2018-07-12 | 2021-05-27 | F Star Therapeutics Ltd | Moleculas de anticuerpo que se unen a cd137 y ox40. |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| AU2019301204B2 (en) | 2018-07-12 | 2025-10-23 | Invox Pharma Limited | Antibody molecules that bind PD-L1 and CD137 |
| WO2020014583A1 (en) | 2018-07-13 | 2020-01-16 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor |
| CN111040034B (zh) * | 2018-10-12 | 2022-08-30 | 广东旋玉健康生物科技有限公司 | 一种抗人cd358的单克隆抗体及其用途 |
| TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| CN113166248B (zh) * | 2018-11-26 | 2022-05-27 | 南京金斯瑞生物科技有限公司 | 人源化抗人ox40单克隆抗体及其制备方法和用途 |
| WO2020119789A1 (en) * | 2018-12-14 | 2020-06-18 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing the same, and use thereof |
| EP3904383A4 (en) * | 2018-12-25 | 2022-08-17 | Hanx Biopharmaceutics, Inc | ANTI-OX40 MONOCLONAL ANTIBODY AND USE THEREOF |
| US10442866B1 (en) | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| MY208565A (en) | 2019-02-27 | 2025-05-15 | Ionis Pharmaceuticals Inc | Modulators of malat1 expression |
| WO2020198338A1 (en) * | 2019-03-25 | 2020-10-01 | Ohio State Innovation Foundation | Combination immunoregulation and uses thereof |
| US20220220430A1 (en) | 2019-05-23 | 2022-07-14 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
| EP3977132A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| WO2021098749A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene (Beijing) Co., Ltd. | Methods of cancer treatment with anti-ox40 antibody in combination with radiation |
| CN114729050A (zh) * | 2019-11-21 | 2022-07-08 | 百济神州有限公司 | 使用抗OX40抗体与PI3激酶δ抑制剂组合治疗癌症的方法 |
| KR20220103105A (ko) * | 2019-11-21 | 2022-07-21 | 베이진 엘티디 | 항-tim3 항체와 병용하여 항-ox40 항체를 사용한 암 치료 방법 |
| CN115151563A (zh) * | 2019-11-21 | 2022-10-04 | 百济神州有限公司 | 使用抗ox40抗体与抗pd1或抗pdl1抗体组合治疗癌症的方法 |
| WO2021098757A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| BR112022011949A2 (pt) | 2019-12-17 | 2022-11-22 | Amgen Inc | Dupla de interleucina-2/agonista do receptor tnf para uso em terapia |
| US20230139700A1 (en) | 2020-03-23 | 2023-05-04 | Bio-Thera Solutions, Ltd. | Development and application of immune cell activator |
| AU2021256799A1 (en) | 2020-04-17 | 2022-11-17 | Hutchison Medipharma Limited | Anti-OX40 antibody and uses thereof |
| EP4149974A1 (en) * | 2020-05-13 | 2023-03-22 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Recombinant proteins with ox40 activating properties |
| CA3190660A1 (en) | 2020-08-31 | 2022-03-03 | George C. Lee | Cell localization signature and immunotherapy |
| JP2023544410A (ja) | 2020-10-05 | 2023-10-23 | ブリストル－マイヤーズ スクイブ カンパニー | タンパク質を濃縮するための方法 |
| CN114457022A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用 |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| CA3196999A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Methods of treating tumors |
| SMT202500208T1 (it) | 2020-12-28 | 2025-07-22 | Bristol Myers Squibb Co | Composizioni anticorpali e metodi per il loro uso |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| US20240317874A1 (en) * | 2021-06-29 | 2024-09-26 | Hifibio (Hk) Limited | Anti-ox40 monoclonal antibody and methods of use thereof |
| JP2025501522A (ja) | 2021-12-17 | 2025-01-22 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | 抗ｏｘ４０抗体及び使用方法 |
| CA3240585A1 (en) | 2021-12-17 | 2023-06-22 | Wenfeng Xu | Anti-ox40 antibodies, multispecific antibodies and methods of use |
| EP4475879A1 (en) | 2022-02-08 | 2024-12-18 | Hookipa Biotech GmbH | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
| KR20240159621A (ko) | 2022-03-18 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | 폴리펩티드를 단리하는 방법 |
| CN114591988B (zh) * | 2022-03-30 | 2023-01-13 | 北京贝来生物科技有限公司 | 一种激活肿瘤免疫的基因修饰干细胞制备方法 |
| WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| CN114966061B (zh) * | 2022-07-28 | 2022-10-21 | 中国食品药品检定研究院 | 一种抗ox40抗体的生物活性检测方法 |
| EP4583999A1 (en) | 2022-09-09 | 2025-07-16 | Bristol-Myers Squibb Company | Methods of separating chelator |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| JP2003511012A (ja) | 1999-09-24 | 2003-03-25 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ３２個のヒト分泌タンパク質 |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| US20080312425A1 (en) | 2004-08-30 | 2008-12-18 | Lonza Biologics Plc. | Ion Exchange Chromatography and Purification of Antibodies |
| PT2650020T (pt) | 2005-05-06 | 2016-12-12 | Providence Health & Services - Oregon | Proteína de fusão de imunoglobulina ox-40 trimérica e métodos do campo de utilização |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| WO2008022746A1 (en) * | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Tumor therapy with an anti-vegf antibody |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| RU2009135824A (ru) * | 2007-02-27 | 2011-04-10 | Дженентек, Инк. (Us) | Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний |
| SG186656A1 (en) * | 2007-12-14 | 2013-01-30 | Bristol Myers Squibb Co | Binding molecules to the human ox40 receptor |
| US8093364B2 (en) | 2008-01-18 | 2012-01-10 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| CN101952454B (zh) | 2008-02-08 | 2014-06-04 | 米迪缪尼有限公司 | 具有减弱的Fc配体亲和性的抗IFNAR1抗体 |
| BRPI1008692B8 (pt) * | 2009-02-17 | 2021-05-25 | Ucb Biopharma Sprl | anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão |
| CA3027071A1 (en) | 2011-01-14 | 2013-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| PH12014500089A1 (en) * | 2011-07-11 | 2014-02-17 | Ichnos Sciences SA | Antibodies that bind to ox40 and their uses |
| CA2845810C (en) | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| EP2812022B1 (en) * | 2012-02-06 | 2019-06-26 | Providence Health & Services - Oregon | Method of monitoring cancer treatment using ox40 agonists |
| CA2865899A1 (en) * | 2012-03-02 | 2013-09-06 | William Redmond | Dual ox40 agonist/il-2 cancer therapy methods |
| CA2905940A1 (en) * | 2013-03-12 | 2014-10-09 | Decimmune Therapeutics, Inc. | Humanized, anti-n2 antibodies |
| MD20180107A2 (ro) * | 2013-03-18 | 2019-06-30 | Biocerox Products B.V. | Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora |
-
2015
- 2015-10-01 TW TW104132442A patent/TW201619200A/zh unknown
- 2015-10-07 ES ES15848683T patent/ES2914177T3/es active Active
- 2015-10-07 RU RU2017115662A patent/RU2709742C2/ru active
- 2015-10-07 MX MX2017004715A patent/MX2017004715A/es unknown
- 2015-10-07 KR KR1020177012413A patent/KR20170064550A/ko not_active Withdrawn
- 2015-10-07 CN CN201580056175.7A patent/CN107074953A/zh active Pending
- 2015-10-07 US US14/877,547 patent/US9738723B2/en active Active
- 2015-10-07 SG SG11201702826XA patent/SG11201702826XA/en unknown
- 2015-10-07 AU AU2015328090A patent/AU2015328090A1/en not_active Abandoned
- 2015-10-07 BR BR112017007170A patent/BR112017007170A2/pt not_active Application Discontinuation
- 2015-10-07 CA CA2963798A patent/CA2963798A1/en not_active Abandoned
- 2015-10-07 JP JP2017518907A patent/JP6794348B2/ja active Active
- 2015-10-07 EP EP15848683.7A patent/EP3204422B1/en active Active
- 2015-10-07 WO PCT/US2015/054490 patent/WO2016057667A1/en not_active Ceased
- 2015-10-08 GB GB1517855.1A patent/GB2536324A/en not_active Withdrawn
- 2015-10-09 AR ARP150103284A patent/AR102239A1/es unknown
-
2017
- 2017-04-03 IL IL251537A patent/IL251537A0/en unknown
- 2017-04-10 CL CL2017000885A patent/CL2017000885A1/es unknown
- 2017-05-04 CO CONC2017/0004516A patent/CO2017004516A2/es unknown
- 2017-06-28 US US15/635,847 patent/US10150815B2/en active Active
-
2018
- 2018-12-10 US US16/215,263 patent/US20190169303A1/en not_active Abandoned
-
2020
- 2020-11-11 JP JP2020187650A patent/JP2021036887A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3204422A1 (en) | 2017-08-16 |
| US10150815B2 (en) | 2018-12-11 |
| ES2914177T3 (es) | 2022-06-07 |
| AU2015328090A1 (en) | 2017-04-27 |
| IL251537A0 (en) | 2017-05-29 |
| GB201517855D0 (en) | 2015-11-25 |
| CN107074953A (zh) | 2017-08-18 |
| KR20170064550A (ko) | 2017-06-09 |
| RU2709742C2 (ru) | 2019-12-19 |
| WO2016057667A1 (en) | 2016-04-14 |
| AR102239A1 (es) | 2017-02-15 |
| US9738723B2 (en) | 2017-08-22 |
| EP3204422B1 (en) | 2022-03-30 |
| RU2017115662A3 (OSRAM) | 2019-05-20 |
| TW201619200A (zh) | 2016-06-01 |
| EP3204422A4 (en) | 2018-08-15 |
| RU2017115662A (ru) | 2018-11-13 |
| CL2017000885A1 (es) | 2017-12-15 |
| CA2963798A1 (en) | 2016-04-14 |
| SG11201702826XA (en) | 2017-05-30 |
| US20160137740A1 (en) | 2016-05-19 |
| US20190169303A1 (en) | 2019-06-06 |
| US20180072808A1 (en) | 2018-03-15 |
| JP2021036887A (ja) | 2021-03-11 |
| BR112017007170A2 (pt) | 2017-12-19 |
| JP2017532037A (ja) | 2017-11-02 |
| JP6794348B2 (ja) | 2020-12-09 |
| GB2536324A (en) | 2016-09-14 |
| MX2017004715A (es) | 2017-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017004516A2 (es) | Anticuerpos anti-ox40 humanizados | |
| PH12020550781A1 (en) | Anti-jagged1 antibodies and methods of use | |
| PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
| PH12016501894A1 (en) | Anti-ox40 antibodies and methods of use | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| MX2017003022A (es) | Anticuerpos anti-cll-1 e inmunoconjugados. | |
| NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
| GEP20217331B (en) | Anti-tigit antibodies | |
| PH12017500877A1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
| PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
| EA201691991A1 (ru) | Мультиспецифические антитела | |
| EA202092435A3 (ru) | Моноклональные антитела против bcma | |
| MX382129B (es) | Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso. | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
| MX2017008456A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| EA201990370A1 (ru) | Терапия рака, связанная с crebbp | |
| EA202092450A2 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
| HK1238261A1 (en) | Novel anti-mfi2 antibodies and methods of use |